These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1154 related articles for article (PubMed ID: 9306028)

  • 21. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users.
    van der Spuy ZM; Sohnius U; Pienaar CA; Schall R
    Contraception; 1990 Dec; 42(6):597-609. PubMed ID: 2128047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of contraceptive steroids on hypothalamic-pituitary function.
    Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
    Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive.
    Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR
    Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of long-term low-dose mifepristone on reproductive function in women.
    Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
    Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mechanism of action of a new low-dosed combined oral contraceptive.
    Dericks-Tan JS; Schneider K; Taubert HD
    Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical investigation of the biological effects of a new combination low-dose oral contraceptive ('Ovostat E').
    Tarkkila T; Hulkko S; Alapiessa U; Kauraniemi T
    Curr Med Res Opin; 1977; 5(3):247-51. PubMed ID: 162661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
    Scott JZ; Kletzky OA; Brenner PF; Mishell DR
    Fertil Steril; 1978 Aug; 30(2):141-5. PubMed ID: 98356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of desogestrel-containing oral contraceptives on vascular reactivity and catecholamine levels.
    Arangino S; Cagnacci A; Angiolucci M; Longu G; Melis GB; Volpe A
    Contraception; 1998 Nov; 58(5):289-93. PubMed ID: 9883384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.